New hope for stubborn nasal polyps: dupilumab shows promise
NCT ID NCT05049122
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tested the drug dupilumab in 25 adults with chronic sinusitis and nasal polyps that weren't helped by other treatments. Participants received injections for up to 52 weeks. The main goal was to see if polyp size decreased by at least 1 point on a standard scale after 24 weeks. The study also looked at safety and other measures of improvement.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Dupilumab (a biologic drug given as an injection)
What this could lead to
If successful, this could offer a new treatment option for people with nasal polyps that don't respond to standard therapies.
What could go wrong
This is a small, single-arm study with only 25 participants, so results may not apply to everyone. As a Phase 4 trial, it confirms safety and effectiveness in a specific group, but unexpected side effects are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC RHINOSINUSITIS WITH NASAL POLYPS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Investigational site JAPAN
Japan, Japan